Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ACE inhibitor drug reduces heart failure in high-risk patients

25.02.2003


The drug ramipril significantly reduced the onset of debilitating and often-fatal heart failure in a large group of high-risk patients, researchers report in today’s rapid access issue of Circulation: Journal of the American Heart Association.



Ramipril, trade-named Altace, is one of a family of high blood pressure medications known as ACE inhibitors. The drugs reduce the risk of death from heart failure – the inability of a weakened or damaged heart to pump enough blood through the body – in people who suffer heart attacks. The American Heart Association estimates that nearly 5 million people in the United States have congestive heart failure.

"This trial extends the benefits of ACE inhibitors beyond what has been previously proven," says lead author Malcolm Arnold, M.D., "It shows, for the first time, that heart failure can be prevented in a broad range of high risk patients."


Researchers found that ramipril reduced the risk of heart failure by 23 percent in patients with cardiovascular disease who still had normal heart pumping function and no previous heart failure. Patients who received the drug also had a lower rate of hospitalization and death because of heart failure.

"The reduction of heart failure in people treated with ramipril was consistent in all major subgroups," says Arnold, professor of medicine, physiology, and pharmacology at the University of Western Ontario and a cardiologist at the London Health Sciences Center in London, Ontario, Canada. "These included patients over 65 years, females, and patients without known hypertension or diabetes." The trial is from the Heart Outcomes Prevention Evaluation (HOPE) study, a randomized trial that followed 9,541 high-risk cardiovascular patients age 55 and older at 267 centers in 19 countries in the Americas and Europe.

In the new analysis, the researchers used data from 9,297 of the HOPE participants who had randomly received either 10 milligrams of ramipril or a placebo daily and were followed for an average of 4.5 years. Their average age was 66 and 73 percent were males. Fifty-three percent had a previous heart attack, 47 percent had a history of hypertension, and 38 percent had diabetes – all risk factors for heart failure.

Researchers defined heart failure as any of the following: poor heart pumping that caused death, or required hospitalization or treatment with ACE inhibitors as determined by a physician, or the appearance of the disease’s typical signs and symptoms. One or more of these components occurred in 951 (10.2 percent) of the participants during the follow-up period.

Ramipril reduced the rate of heart failure by a significant 22 percent in the 8,315 patients who did not suffer a heart attack. Among the 1,029 people who had a heart attack, those taking ramipril had a 13 percent lower rate of heart failure, although this finding did not reach statistical significance, Arnold says.

In addition, patients treated with ramipril whose systolic blood pressure (the upper number in a blood pressure reading) was above the median had a 33 percent reduction in risk of heart failure compared to a 9 percent reduction for those below the median.

In an accompanying editorial, Jennifer V. Linseman, Ph.D., and Michael R. Bristow, M.D., Ph.D., of the University of Colorado Health Sciences Center in Denver, note that for a majority of the participants in this analysis were classified with heart failure if their symptoms were severe enough that they need to be treated with ACE inhibitors.

This is a "softer endpoint that death or hospitalization . . . ." they write. "Therefore results, while still encouraging, should be viewed with some caution."

Taken with previous results from the HOPE study, they say: "these data support the idea that ACE inhibitors exert a measurable cardiovascular-protective effect in a broad range of patients at high-risk of cardiovascular complications, and these effects are additional to and independent of blood pressure lowering."

Arnold’s co-authors are Salim Yusuf, M.D.; James Young, M.D.; James Mathew, M.D.; David Johnstone, M.D.; Alvaro Avezum, M.D.; Eva Lonn, M.D.; Janice Pogue; and Jackie Bosch on behalf of the HOPE investigators.


CONTACT: For journal copies only, please call: 214-706-1396

For other information, call:
Carole Bullock: 214-706-1279
Bridgette McNeill: 214-706-1135

Carole Bullock | EurekAlert!
Further information:
http://www.americanheart.org/

More articles from Health and Medicine:

nachricht NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures
17.11.2017 | National Institute of Standards and Technology (NIST)

nachricht High speed video recording precisely measures blood cell velocity
15.11.2017 | ITMO University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

Im Focus: Novel Nano-CT device creates high-resolution 3D-X-rays of tiny velvet worm legs

Computer Tomography (CT) is a standard procedure in hospitals, but so far, the technology has not been suitable for imaging extremely small objects. In PNAS, a team from the Technical University of Munich (TUM) describes a Nano-CT device that creates three-dimensional x-ray images at resolutions up to 100 nanometers. The first test application: Together with colleagues from the University of Kassel and Helmholtz-Zentrum Geesthacht the researchers analyzed the locomotory system of a velvet worm.

During a CT analysis, the object under investigation is x-rayed and a detector measures the respective amount of radiation absorbed from various angles....

Im Focus: Researchers Develop Data Bus for Quantum Computer

The quantum world is fragile; error correction codes are needed to protect the information stored in a quantum object from the deteriorating effects of noise. Quantum physicists in Innsbruck have developed a protocol to pass quantum information between differently encoded building blocks of a future quantum computer, such as processors and memories. Scientists may use this protocol in the future to build a data bus for quantum computers. The researchers have published their work in the journal Nature Communications.

Future quantum computers will be able to solve problems where conventional computers fail today. We are still far away from any large-scale implementation,...

Im Focus: Wrinkles give heat a jolt in pillared graphene

Rice University researchers test 3-D carbon nanostructures' thermal transport abilities

Pillared graphene would transfer heat better if the theoretical material had a few asymmetric junctions that caused wrinkles, according to Rice University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

NASA detects solar flare pulses at Sun and Earth

17.11.2017 | Physics and Astronomy

NIST scientists discover how to switch liver cancer cell growth from 2-D to 3-D structures

17.11.2017 | Health and Medicine

The importance of biodiversity in forests could increase due to climate change

17.11.2017 | Studies and Analyses

VideoLinks
B2B-VideoLinks
More VideoLinks >>>